导电系统节奏与心力衰竭中的双心室节奏与减少喷射分数:随机对照试验的系统性审查和元分析
Iuri Ferreira Felix1, Michelle Collini2, Rafaela Fonseca3
1Department of Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota.
Heart rhythm
|February 21, 2024
概括
导电系统节奏 (CSP) 与双心室节奏 (BVP) 相比,在需要心脏再同步的心力衰竭患者中具有显著的优势. CSP提高了QRS持续时间,NYHA功能类和弹射率,这表明它是QRS.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 导电系统节奏 (CSP) 是用于心脏再同步治疗 (CRT) 的双心脏节奏 (BVP) 的新兴替代方案.
- 患有心力衰竭,排气分数减少 (HFrEF) 和心室失同症的患者是CRT的候选人,但CSP的比较疗效仍在研究中.
研究的目的:
- 评估和比较CSP与BVP在被诊断为HFrEF的患者心脏再同步的临床结果.
- 综合随机对照试验 (RCT) 的证据,以确定每个节奏策略的相对好处和缺点.
主要方法:
- 在HFrEF患者中对CRT进行CSP和BVP进行比较的RCT的系统审查和元分析.
- 在PubMed,Scopus和Cochrane数据库中进行了搜索.
- 用随机效应模型分析数据,通过I2统计评估异质性.
主要成果:
- 与BVP相比,CSP显示QRS持续时间显著减少 (MD -13.34毫秒),并且改善了纽约心脏协会 (NYHA) 的功能类 (SMD -0.37) .
- 左心室喷射分数 (LVEF) 与CSP显著增加 (MD 2.06%).
- 没有观察到左心室末缩体积,捕获值或手术时间的显著差异.
结论:
- 在需要心脏再同步的HFrEF患者中,导电系统节奏可能与双心室节奏相比,提供更好的心电图,心声图和症状益处.
- CSP是一种潜在的更有效的CRT策略,需要在临床实践中进行进一步的研究和考虑.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.5K
相关概念视频
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Conduction System of the Heart
6.9K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
6.9K
